Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Hand-out
Press Releases
Soligenix, Inc.  
October 22, 2024

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis

avatar profile Olean Times Herald

Olean Times Herald


Local & Social